A potent alpha2-adrenergic agonist, romifidine is classified as a sedative/analgesic with muscle relaxant properties. Alpha-2 receptors are found in the CNS and several tissues peripherally; both presynaptically and postsynaptically. In the CNS, the primary action is a feedback inhibition of norepinephrine release. Opioids and alpha-2 agonists may have synergistic analgesic effects. Pharmacologic effects of romifidine include sedation, analgesia, and reduced catecholamine release from the CNS. Thermoregulatory mechanisms may be altered. Peripherally, an initial vasoconstrictive response occurs with increases in blood pressure. Within minutes a hypotensive phase occurs. Heart rate can significantly decrease secondary to a vagal response to hypertension. A second-degree atrioventricular block may also occur. Antimuscarinic agents can prevent bradycardia, but their use is controversial as they can potentially cause hypertension, increased myocardial oxygen demand, and reduced GI motility. Alpha-2 agonists can transiently slow duodenal motility and increase micturation in horses and can inhibit insulin release from pancreatic islet cells resulting in hyperglycemia. Other effects seen in horses in romifidine hcl 805 806 romifidine hcl clude sweating, mydriasis, decreases in hematocrit, and increased uterine pressure in non-pregnant mares. In horses, when compared with other alpha-2 agonists (xylazine, detomidine, medetomidine), romifidine does not appear to cause as much ataxia at sedative dosages and has the longest duration of sedation. Duration of analgesia is shorter than the duration of sedation.
Ronidazole is a nitroimidazole antibiotic/antiparasitic drug that appears to be useful in treating _Tritrichomonas foetus_ infections in cats. The drug is not commercially available in the USA and must be compounded from bulk powder by a compounding pharmacy. The drug is also used for treating Trichomonas infections in nonfood animal birds.
劑量數字暫停提供:VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容,DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源;計算機可手動輸入劑量換算。
目前通用 API 無法同時強制具名產品/NADA、濃度、鹽型與基質換算、馬匹生命階段、IV 途徑、適應症與麻醉時序、法域、食品用途、停藥期、交互作用與連續監測。因此即使九張現行馬用標籤卡有官方證據,全部十五張數值卡仍不得進入計算器或飼主端。
DRUGAPI 劑量審查引用的獸醫官方標示(各標示只適用於其產品、物種與法域,不可互換)
依出現頻率分組;嚴重副作用獨立列出,臨床上需立即辨識。
renal